Acute kidney injury associated with anti-PD-1 and anti-PD-L1 drugs: a meta-analysis of randomized clinical trials

• Published in: Immunopharmacology and immunotoxicology Vol. 46; no. 4; pp. 470 - 481
• Main Authors: Lima, Isabela Gonçalves, Silva, Isabele Benck Usiro Cabral da, Pípolo, Vitória Carpentieri, Delfino, Vinicius Daher Alvares, Bignardi, Paulo Roberto
• Format: Journal Article
• Language: English
• Published: England 01-08-2024
• Subjects: Acute Kidney Injury - chemically induced; Acute Kidney Injury - epidemiology; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - immunology; Humans; Immune Checkpoint Inhibitors - adverse effects; Neoplasms - drug therapy; Neoplasms - immunology; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Programmed Cell Death 1 Receptor - immunology; Randomized Controlled Trials as Topic; pembrolizumab; durvalumab; nivolumab; cemiplimab; acute kidney injury; atezolizumab; Immune check-point inhibitors
• ISSN: 0892-3973; 1532-2513; 1532-2513
• DOI: 10.1080/08923973.2024.2360071

Immune Checkpoint Inhibitors (ICI) have been widely used in treating different types of cancer. They increase survival in many oncologic patients and enable cancer-specific therapy. Acute Kidney Injury (AKI) is one of the adverse effects associated with using ICI, where knowledge of the prevalence and renal histological findings are still reasons for discussion.
Therefore, this meta-analysis evaluates the association between ICI use and AKI.
The search was performed in PubMed, Lilacs, and Cochrane platforms. Studies published up to December 1, 2022, were included.
A total of 16 studies met the established PICOT criteria and were included in this review. Comparing the ICI plus chemotherapy against chemotherapy alone, the relative risk (RR) for AKI's development with ICI use was 2.89 (95%CI 1.37-6.10). In the analyses by class and drug type, programmed cell death 1 monoclonal antibody (anti-PD-1) showed an increased risk of 2.11 (95%CI 1.26-3.52), and pembrolizumab demonstrated a risk of AKI (RR= 2.77, 95%CI 1.46-5.26). Likewise, regarding the severity of AKI, AKI grade 3 or higher was more common in the ICI plus chemotherapy compared to the chemotherapy group: 3.66 (95%CI 1.19-11.30), while the subgroup analyses pooled studies comparing ICI alone versus chemotherapy alone in the control group did not demonstrate an association with AKI.
These findings suggest that ICI use is associated with an increased risk of AKI and that anti-PD-1 use is associated with a higher incidence of renal adverse events than programmed cell death ligand 1 monoclonal antibody (anti-PD-L1). Studies with adequate power and well-defined criteria for acute interstitial nephritis, nowadays taken as a synonym for AKI related to ICI, are necessary.